Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | TYR | P14679 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | TTR | P02766 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10389523 | 1.00 | CA12 (0.64) | CA12CA1CA2TYRCA7 | |
| SCHEMBL8082171 | 0.86 | KMT2A (0.75) | KDM4EMAPTKMT2ATTRMEN1 | |
| Acetic Acid Methyl Ester SCHEMBL28313629 | 0.86 | GSK3B (0.67) | CA12CA1CA2TYRCA7 | |
| SCHEMBL5057418 | 0.85 | CA12 (0.84) | CA12CA1CA2TYRCA7 | |
| SCHEMBL71224 | 0.85 | CA12 (0.84) | CA12CA1CA2TYRCA7 | |
| SCHEMBL14226869 | 0.85 | CA12 (0.62) | CA12CA1CA2TYRCA7 | |
| SCHEMBL27428673 | 0.85 | CA12 (0.62) | CA12CA1CA2TYRCA7 | |
| SCHEMBL7691349 | 0.84 | MAPT (0.57) | CA12CA1CA2TYRCA7 | |
| SCHEMBL7691353 | 0.84 | MAPT (0.57) | CA12CA1CA2TYRCA7 | |
| SCHEMBL30105639 | 0.84 | GSK3B (0.73) | CA12CA1CA2TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59196813-A | — | — | None | — | — | JP | disclosed |
| US-20220315686-A1 | CURABLE COMPOSITION, CURED SUBSTANCE, OPTICAL MEMBER, AND LENS | FUJIFILM CORPORATION (JP) | 2022-10-06 | — | — | US | disclosed |
| WO-2021132037-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER AND LENS | 富士フイルム株式会社 | 2021-07-01 | — | — | WO | disclosed |
| EP-1916234-B1 | CYCLOPROPANECARBOXYLIC ACID COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8535769-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and oriented film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20120172560-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8153694-B2 | Cyclopropanecarboxylic acid compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153694-B2 | Cyclopropanecarboxylic acid compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153694-B2 | Cyclopropanecarboxylic acid compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| EP-1916234-A1 | CYCLOPROPANECARBOXYLIC ACID COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
| US-4978523-A | P-hydroxycinnamides to remove pigment deposits in skin | KAO CORPORATION (JP) | 1990-12-18 | — | — | US | disclosed |
| JP-S59196813-A | MELANIN INHIBITOR | KAO CORP | 1984-11-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144806-A1 | Cyclopropanecarboxylic Acid Compound | GPR65, GPR34, GPR68 | CA12 2025/4885CA1 1938/4885CA2 929/4885 |
| US-20120172560-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM | CRY1, NAP1L1, LAS1L | CA12 982/4885CA1 1269/4885CA2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.